GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Net-Net Working Capital

Seer (SEER) Net-Net Working Capital : $4.25 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Seer Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Seer's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $4.25.

The industry rank for Seer's Net-Net Working Capital or its related term are showing as below:

SEER's Price-to-Net-Net-Working-Capital is ranked better than
97.52% of 926 companies
in the Biotechnology industry
Industry Median: 4.19 vs SEER: 0.41

Seer Net-Net Working Capital Historical Data

The historical data trend for Seer's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Net-Net Working Capital Chart

Seer Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial -0.78 7.11 5.93 6.08 4.40

Seer Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.98 4.43 4.66 4.40 4.25

Competitive Comparison of Seer's Net-Net Working Capital

For the Biotechnology subindustry, Seer's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seer's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Seer's Price-to-Net-Net-Working-Capital falls into.



Seer Net-Net Working Capital Calculation

Seer's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(316.224+0.75 * 4.831+0.5 * 4.491-39.365
-0-0)/64.2987
=4.40

Seer's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(308.55+0.75 * 3.815+0.5 * 5.809-38.407
-0-0)/64.9367
=4.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Seer  (NAS:SEER) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Seer Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Seer's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Seer (SEER) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Executives
Elona Esq. Kogan officer: General Counsel and Secretary C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad director, 10 percent owner, officer: CEO and Chair of the Board C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas officer: Chief Commercial Officer C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn officer: Chief Financial Officer 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan director, officer: President & COO C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani director C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz director C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer director C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005